Telehealth palliative care for patients with chronic graft-versus-host disease
Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease
This study is testing whether telehealth palliative care can help improve the quality of life for patients with moderate to severe chronic graft-versus-host disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT06458127 on ClinicalTrials.gov |
What this trial studies
This research evaluates the feasibility and acceptability of a telehealth palliative care intervention for patients suffering from moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a significant complication following allogeneic hematopoietic cell transplantation, affecting over 50% of survivors and leading to various debilitating symptoms and psychological distress. The study aims to provide support through tele-palliative care visits, addressing both the physical and emotional challenges faced by these patients. By utilizing telehealth, the intervention seeks to improve the quality of life for individuals managing this complex condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients over 18 years old with moderate to severe cGVHD who can communicate in English.
Not a fit: Patients with acute or unstable psychiatric or cognitive conditions, or those already receiving palliative care, may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly enhance the quality of life for patients suffering from chronic graft-versus-host disease.
How similar studies have performed: While this approach is innovative, similar telehealth interventions in palliative care have shown promise in improving patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1) Adult patients (\>18 years) * 2) Have moderate to severe cGVHD based on their oncology clinician assessment as documented in the electronic health record. * 3) Ability to comprehend and speak English, and to read and respond to questions in English Please note that this is a proof-of-concept study, and we only include patients who comprehend, read, and respond to questions in English since the study instruments are all available in English. However, as we have done in prior studies, we will expand the population in a future efficacy trial. Exclusion Criteria: * 1) Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures * 2) Patients who have already consulted or are currently consulting palliative care
Where this trial is running
Boston, Massachusetts
- Massachusetts General Hospital (MGH) — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Study coordinator: Areej El-Jawahri, MD
- Email: ael-jawahri@mgb.org
- Phone: 617-724-4000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.